Abstract
Background: Poly (ADP-ribosyl) polymerase 1 (PARP1) is important in maintaining genomic stability, repairing DNA damage, and regulating transcriptional processes. Altered PARP1 activity is associated with a multitude of pathologies especially cancer. The broad application prospects of PARP1 inhibitors attract many well-known pharmaceutical companies, which promotes the development of PARP1 inhibitors.
Objective: Present review aims to introduce PARP1 inhibitors by their structures and try to point out future development direction of PARP1 inhibitors. Method: Details regarding the PARP1and PARP1 inhibitors are obtained from PubMed literatures and patent databases. Conclusion: The action mode of PARP1 inhibitors developed so far is competing with NAD+ for the catalytic site of PARP1. Using such inhibitors affects multiple NAD+-dependent enzymatic pathways, which results in secondary toxic effects. Designing inhibitors targeting other binding sites on the PARP1 protein is a strategy to bypass this pitfall. Analyzing the structure-activity relationships of active PARP1 inhibitors described in the patents, we conclude that for the binding activity, amide group, aromatic ring or heterocyclic ring with rich electronics and heteroatom-substituted in the meta position of amide group are essential. Big substituents introduced in the heterocyclic ring can enhance inhibitory activity and improve solubility or other physicochemical properties. Clinical trials of PARP1 inhibitor were focused on cancer therapies and have achieved remarkable results.Keywords: Cancer, clinical trials, DNA repair, inhibitor, NAD+, PARP1, structure.
Recent Patents on Anti-Cancer Drug Discovery
Title:Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Volume: 12 Issue: 3
Author(s): Mengda Cao, Xi Sun, Yanjun Zhou, Wen Huang, Ling Meng*Ji-Fu Wei*
Affiliation:
- Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029,China
- First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029,China
Keywords: Cancer, clinical trials, DNA repair, inhibitor, NAD+, PARP1, structure.
Abstract: Background: Poly (ADP-ribosyl) polymerase 1 (PARP1) is important in maintaining genomic stability, repairing DNA damage, and regulating transcriptional processes. Altered PARP1 activity is associated with a multitude of pathologies especially cancer. The broad application prospects of PARP1 inhibitors attract many well-known pharmaceutical companies, which promotes the development of PARP1 inhibitors.
Objective: Present review aims to introduce PARP1 inhibitors by their structures and try to point out future development direction of PARP1 inhibitors. Method: Details regarding the PARP1and PARP1 inhibitors are obtained from PubMed literatures and patent databases. Conclusion: The action mode of PARP1 inhibitors developed so far is competing with NAD+ for the catalytic site of PARP1. Using such inhibitors affects multiple NAD+-dependent enzymatic pathways, which results in secondary toxic effects. Designing inhibitors targeting other binding sites on the PARP1 protein is a strategy to bypass this pitfall. Analyzing the structure-activity relationships of active PARP1 inhibitors described in the patents, we conclude that for the binding activity, amide group, aromatic ring or heterocyclic ring with rich electronics and heteroatom-substituted in the meta position of amide group are essential. Big substituents introduced in the heterocyclic ring can enhance inhibitory activity and improve solubility or other physicochemical properties. Clinical trials of PARP1 inhibitor were focused on cancer therapies and have achieved remarkable results.Export Options
About this article
Cite this article as:
Cao Mengda , Sun Xi , Zhou Yanjun, Huang Wen, Meng Ling *, Wei Ji-Fu *, Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (3) . https://dx.doi.org/10.2174/1574892812666170508124932
DOI https://dx.doi.org/10.2174/1574892812666170508124932 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis
Current Diabetes Reviews The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research Analysis of Heart Rate Variability and Implication of Different Factors on Heart Rate Variability
Current Cardiology Reviews Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Anti-Apoptotic Effect of Human Telomerase Reverse Transcriptase on Endothelial Cells under Oxidative Stress, Independent of Telomere Elongation and Telomerase Activity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Biosynthesis and Characterization of a Novel Fibrinolytic Alkaline Serine Protease from Newly Isolated <i>Bacillus flexus</i> BF12 for Biomedical Applications
Current Pharmaceutical Biotechnology A Review of Gene Expression Profiling of Human Embryonic Stem Cell Lines and their Differentiated Progeny
Current Stem Cell Research & Therapy Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Standardized <i>Cyanthillium cinereum</i> (L.) H.Rob. Extract and Determination of its Biological Activities
The Natural Products Journal Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Obesity for the Prevention of Chronic Cardiovascular Disease Through Gut Microbiota-Herb Interactions: An Opportunity for Traditional Herbs
Current Pharmaceutical Design New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bioresorbable Vascular Scaffold: Our Initial Experience
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial [Hot topic: Interstitial Lung Disease with Connective Tissue Diseases (Guest Editor: Eric Matteson)]
Current Rheumatology Reviews